Prostatic androgen repressed message-1 (PARM-1) may play a role in prostatic cell immortalisation

Prostate

Volumn 56, Issue 3, 2003, Pages 220-230

  Cornet, Anne M ^a   Hanon, Emmanuel ^a   Reiter, Eric R ^a   Bruyninx, Marc ^a   Nguyen, Viet Ha ^a   Hennuy, Benoît R ^a   Hennen, Georges P ^a   Closset, Jean L ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

MAT LyLu cells; PARM 1; Prostate; Survival; Telomerase; TLP1

Indexed keywords

ANDROGEN; COMPLEMENTARY DNA; DOXYCYCLINE; PROSTATIC ANDROGEN REPRESSED MESSAGE 1; TELOMERASE; TELOMERASE PROTEIN COMPONENT 1; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL IMMORTALIZATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; GENE; GENE OVEREXPRESSION; MALE; MOLECULAR CLONING; NONHUMAN; PRECANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; RAT; TLP1 GENE; TRANSCRIPTION REGULATION; TUMOR CELL LINE;

ANDROGEN-BINDING PROTEIN; ANDROGENS; ANIMALS; APOPTOSIS; CELL SURVIVAL; GENE EXPRESSION REGULATION; MALE; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, WISTAR; TELOMERASE; TUMOR CELLS, CULTURED;

EID: 0041669582     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10254     Document Type: Article

References (45)

1. Isaacs JT, Coffey DS. Androgenic control of prostatic growth: Regulation of steroid levels. UICC Monogr (Prostatic Cancer) 1979;48:112-122.
2. Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: Initial threshold concept. Prostate 1987;11:41-50.
3. English HF, Drago JR, Santen RJ. Cellular response to androgen depletion and repletion in the rat ventral prostate: Autoradiography and morphometric analysis. Prostate 1985;7:41-51.
4. English HF, Santen RJ, Isaacs JT. Response of glandular vs basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate 1987;11:229-242.
5. Rouleau M, Leger JG, Tenniswood M. Ductal heterogeneity of cytokeratins, gene expression and cell death in the rat ventral prostate. Mol Endocrinol 1990;4:2003-2013.
6. Bruyninx M, Hennuy B, Cornet A, Houssa P, Daukandt M, Reiter E, Poncin J, Closset J, Hennen G. A novel gene overexpressed in the prostate of castrated rats: Hormonal regulation, relationship to apoptosis and to acquired prostatic cell androgen-independance. Endocrinology 1999;140(10):4789-4799.
7. Leger JG, Montpetit ML, Tenniswood MP. Characterization and cloning of androgen-repressed mRNAs from rat ventral prostate. Biochem Biophys Res Commun 1987;147:196-203.
8. Bettuzzi S, Hiipakka RA, Gilna P, Liao S. Identification of an androgen-repressed mRNA in rat ventral prostate as coding for sulfated glycoprotein 2 by cDNA cloning and sequence analysis. Biochem J 1989;257:293-296.
9. Fritz IB, Murphy B. Clusterin: Insights into a multifunctional protein. Trends Endocrinol Metab 1993;4:41-45.
10. Rosenberg ME, Silkensen J. Clusterin: Physiologic and pathologic considerations. Int J Biochem Cell Biol 1995;27:633-645.
11. Bettuzzi S, Astancolle S, Guidetti G, Moretti R, Tiozzo R, Corti A. Clusterin (SGP2) gene expression is cell cycle dependent in normal human dermal fibroblasts. FEBS Lett 1999;448:297-300.
12. Yang C, Yeh S, Leskov K, Odegaard E, Hsu H, Chang C, Kinsella TJ, Chen DJ, Boothman DA. Isolation of Ku70-binding proteins (KUBs). Nucleic Acids Res 1999;27:2165-2174.
13. Bettuzzi S, Davalli P, Astancolle S, Carani C, Madeo B, Tampieri A, Corti A. Tumor progression is accompanied by significant changes in the levels of expression of polyamine metabolism regulatory genes and clusterin (sulfted glycoprotein 2) in human prostate cancer specimens. Cancer Res 2000;60:28-34.
14. Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H. Transcriptional activation by tetracycline in mammalian cells. Science 1995;268:1766-1769.
15. Isaacs JT, Isaacs WB, Feitz WFJ, Cheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
16. Lowry OH, Rosebrough NJ, Farr AL, Randall RS. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193:265-275.
17. Chomczinski P, Sacchi N. Single step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroforme extraction. Anal Biochem 1987;162:156-159.
18. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortalized cells and cancer. Science 1994;266:2011-2015.
19. Nakayama JI, Saito M, Nakamura H, Matsuura A, Ishikawa F. TLP1: A gene encoding a protein component of mammalian telomerase is a novel member of WD repeats family. Cell 1997; 88:875-884.
20. Meeker AK, Sommerfeld HJ, Coffey DS. Telomerase is activated in the prostate and seminal vesicles of the castrated rat. Endocrinology 1996;137:5743-5746.
21. English HF, Kyprianou N, Isaacs JT. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate 1989;15:233-251.
22. Lin A, Chan YL, Jones R, Wool IG. The primary structure of rat ribosomal protien S12. J Biol Chem 1987;262:14343-14351.
23. Bettuzzi S, Zoli M, Ferraguti F, Ingletti MC, Agnati LF, Corti A. Regional and cellular distribution within the rat prostate of two mRNA species undergoing opposite regulation by androgens. J Endocrinol 1992;132:361-367.
24. Gonos ES, Derventzi A, Kveiborg M, Agiostratidou G, Kassem M, Clark BFC, Jat PS, Rattan SIS. Cloning and identification of genes that associate with mammalian replicative senescence. Exp Cell Res 1998;240:66-74.
25. Mitchell R, Bacher M, Bernhagen J, Pushkarskaua T, Seldin MF, Bucala R. Cloning and characterzation of the gene for mouse macrophage migration inhibitory factor (MIF). J Immunol 1995;154:3863-3870.
26. Arcuri F, Teresa del vecchio M, de Santi MM, Lalinga AV, Pallini V, Bini L, Bartolommei S, Parigi S, Cintorino M. Macrophage migration inhibitory factor in the human prostate: identification and immunocytochemical localization. Prostate 1999;39:159-165.
27. Buttyan R, Zakeri Z, Lochshin R, Wolgemuth D. Cascade induction of c-fos, c-myc, and heat shock 70K transcripts during regression of the rat ventral prostate gland. Mol Endocrinol 1988;2:650-657.
28. Briehl MM, Miesfeld RL. Isolation and characterization of transcripts induced by androgen withdrawal and apoptotic cell death in the rat ventral prostate. Mol Endocrinol 1991;5:1381-1388.
29. Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996;28:251-265.
30. Nickerson T, Pollak M, Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 1998;139:807-810.
31. Bruyninx M, Ammar H, Reiter E, Cornet A, Closset J. Genes upregulated during castration-induced rat prostatic apoptosis: Cloning and characterization of new cDNAs. BJU Int 2000;85:1-11.
32. Sensibar JA, Sutkowski DM, Raffo A, Buttyan R, Griswold MD, Sylvester SR, Kozlowski JM, Lee C. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (Clusterin). Cancer Res 1995;55:2431-2437.
33. Rhyu MS. Telomeres, telomerase, and immortality. J Natl Cancer Inst 1995;87:884-893.
34. Harley CB, Illeponteau B. Telomeres and telomerase in aging and cancer. Curr Opin Genet Dev 1995;5:249-255.
35. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu C, Morin GB, Harley CB, Shay JW, Lichtsteiner S, Wright WE. Extension of lifespan by introduction of telomerase into normal human cells. Science 1998;279:349-352.
36. Zhang W, Kapusta LR, Slingerland JM, Klotz LH. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998;58:619-621.
37. Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, Johannes FJ, Roger T, Calandra T, Kapurniotu A, Grell M, Finkelmeier D, Brunner H, Bernhagen J. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000;408:211-215.
38. Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T, Fujiwara Y, Yano M, Miyata H, Kishi K, Nagagawa H, Shamma A, Monden M. Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer 2001;85(3):412-421.
39. Glinsky GV, Glinsky W, Ivanova AB, Heuser JN. Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms. Cancer Lett 1997;115:185-193.
40. Qiu G, Almed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM. Mutually exclusive expression patterns of bcl-2 and par-4 in human prostate tumors consistent with downregulation of bcl-2 by par-4. Oncogene 1999;18:623-631.
41. Holt SE, Glinsky VV, Ivanova AB, Glinsky GV. Resistance to apoptosis in human cells conferred by telomerase function and telomere stability. Mol Carcinog 1999;25:241-248.
42. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsiesh JT, Tu SM, Campbell ML. Expression of the protooncogene Bcl-2 protein in the prostate and association with emergence of androgen-independent prostate cancer. Cancer Res 1992;52:6940-6944.
43. Raffo AJ, Perlman H, Chen M-W, Day ML, Strietman JS, Buttyan R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55:4438-4445.
44. Mandal M, Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997;272:14183-14187.
45. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-468.